SG11201801365YA - NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF - Google Patents
NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOFInfo
- Publication number
- SG11201801365YA SG11201801365YA SG11201801365YA SG11201801365YA SG11201801365YA SG 11201801365Y A SG11201801365Y A SG 11201801365YA SG 11201801365Y A SG11201801365Y A SG 11201801365YA SG 11201801365Y A SG11201801365Y A SG 11201801365YA SG 11201801365Y A SG11201801365Y A SG 11201801365YA
- Authority
- SG
- Singapore
- Prior art keywords
- salt
- pyrimidine compound
- novel pyrazolo
- pyrazolo
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015172354 | 2015-09-01 | ||
PCT/JP2016/075380 WO2017038838A1 (ja) | 2015-09-01 | 2016-08-31 | 新規なピラゾロ[3,4-d]ピリミジン化合物又はその塩 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201801365YA true SG11201801365YA (en) | 2018-03-28 |
Family
ID=58188946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201801365YA SG11201801365YA (en) | 2015-09-01 | 2016-08-31 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF |
Country Status (20)
Country | Link |
---|---|
US (2) | US9920060B2 (pt) |
EP (1) | EP3345907B1 (pt) |
JP (1) | JP6141568B1 (pt) |
KR (1) | KR102075886B1 (pt) |
CN (1) | CN108349981B (pt) |
AU (1) | AU2016317521B2 (pt) |
BR (1) | BR112018004175B8 (pt) |
CA (1) | CA2997051C (pt) |
DK (1) | DK3345907T3 (pt) |
ES (1) | ES2799520T3 (pt) |
HK (1) | HK1257146A1 (pt) |
MX (1) | MX2018002520A (pt) |
MY (1) | MY191938A (pt) |
PH (1) | PH12018500437A1 (pt) |
PL (1) | PL3345907T3 (pt) |
PT (1) | PT3345907T (pt) |
RU (1) | RU2705579C2 (pt) |
SG (1) | SG11201801365YA (pt) |
TW (1) | TWI659957B (pt) |
WO (1) | WO2017038838A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017503803A (ja) | 2014-01-10 | 2017-02-02 | シャンハイ バーディー バイオテック インコーポレイテッド | Egfr発現腫瘍を処置するための化合物及び組成物 |
MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于***的抗-egfr组合 |
PT3269370T (pt) | 2016-02-23 | 2020-03-05 | Taiho Pharmaceutical Co Ltd | Novo composto de pirimidina condensada ou sal do mesmo |
AU2018228114B2 (en) * | 2017-02-28 | 2022-04-07 | Taiho Pharmaceutical Co., Ltd. | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
CN106967303A (zh) * | 2017-05-02 | 2017-07-21 | 杭州福莱蒽特精细化工有限公司 | 一种艳色兰偶氮染料及其制备方法和应用 |
WO2020045475A1 (ja) | 2018-08-29 | 2020-03-05 | 大鵬薬品工業株式会社 | ピラゾロ[3,4-d]ピリミジンの結晶 |
TWI769395B (zh) * | 2018-08-29 | 2022-07-01 | 日商大鵬藥品工業股份有限公司 | 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑 |
KR102640463B1 (ko) * | 2019-01-11 | 2024-02-23 | 다이호야쿠힌고교 가부시키가이샤 | 피리미딘 화합물 또는 그 염 |
WO2021164697A1 (zh) * | 2020-02-18 | 2021-08-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的酰胺衍生物及其组合物及用途 |
CN111440138A (zh) * | 2020-04-30 | 2020-07-24 | 中国林业科学研究院林产化学工业研究所 | 具有hdac抑制和抗肿瘤活性的新型漆酚基异羟肟酸衍生物的合成方法 |
WO2022014640A1 (ja) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ |
TW202216717A (zh) | 2020-07-15 | 2022-05-01 | 日商大鵬藥品工業股份有限公司 | 嘧啶化合物之結晶 |
CA3189460A1 (en) | 2020-07-15 | 2022-01-20 | Taiho Pharmaceutical Co., Ltd. | Egfr inhibitor |
IL301532A (en) | 2020-09-23 | 2023-05-01 | Scorpion Therapeutics Inc | History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment |
WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
WO2022072632A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
CA3194724A1 (en) * | 2020-10-05 | 2022-04-14 | Dana-Farber Cancer Institute, Inc. | Potent and selective inhibitors of her2 |
IL301929A (en) | 2020-10-09 | 2023-06-01 | Scorpion Therapeutics Inc | Heterocyclic inhibitors of EGFR and/or 2HER for use in cancer treatment |
WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
WO2023147311A1 (en) * | 2022-01-25 | 2023-08-03 | KSQ Therapeutics, Inc. | Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors |
WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
CN114736207B (zh) * | 2022-04-28 | 2023-03-31 | 武汉九州钰民医药科技有限公司 | 一种小分子her2抑制剂的制备工艺 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE403428T1 (de) * | 2003-06-27 | 2008-08-15 | Pfizer Prod Inc | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren |
AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
US20070135387A1 (en) | 2005-12-08 | 2007-06-14 | Michaelides Michael R | Inhibitors of protein kinases |
CN101007814A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯并六元杂环化合物及其在医药上的用途 |
PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
EP2139487B1 (en) * | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
WO2012158764A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US9138436B2 (en) * | 2011-07-13 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
ES2516392T3 (es) | 2012-01-19 | 2014-10-30 | Taiho Pharmaceutical Co., Ltd. | Compuesto de alquinilbenceno 3,5-disustituido y sal del mismo |
US9415050B2 (en) * | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
EP2947086B1 (en) * | 2013-08-12 | 2018-01-03 | Taiho Pharmaceutical Co., Ltd. | Novel fused pyrimidine compound or salt thereof |
-
2016
- 2016-08-31 PT PT168418689T patent/PT3345907T/pt unknown
- 2016-08-31 DK DK16841868.9T patent/DK3345907T3/da active
- 2016-08-31 SG SG11201801365YA patent/SG11201801365YA/en unknown
- 2016-08-31 KR KR1020187009035A patent/KR102075886B1/ko active IP Right Grant
- 2016-08-31 MY MYPI2018700648A patent/MY191938A/en unknown
- 2016-08-31 AU AU2016317521A patent/AU2016317521B2/en active Active
- 2016-08-31 PL PL16841868T patent/PL3345907T3/pl unknown
- 2016-08-31 MX MX2018002520A patent/MX2018002520A/es active IP Right Grant
- 2016-08-31 CA CA2997051A patent/CA2997051C/en active Active
- 2016-08-31 TW TW105127978A patent/TWI659957B/zh active
- 2016-08-31 WO PCT/JP2016/075380 patent/WO2017038838A1/ja active Application Filing
- 2016-08-31 CN CN201680063691.7A patent/CN108349981B/zh active Active
- 2016-08-31 RU RU2018111439A patent/RU2705579C2/ru active
- 2016-08-31 EP EP16841868.9A patent/EP3345907B1/en active Active
- 2016-08-31 ES ES16841868T patent/ES2799520T3/es active Active
- 2016-08-31 JP JP2017513832A patent/JP6141568B1/ja active Active
- 2016-08-31 BR BR112018004175A patent/BR112018004175B8/pt active IP Right Grant
-
2017
- 2017-04-20 US US15/492,442 patent/US9920060B2/en active Active
-
2018
- 2018-02-28 PH PH12018500437A patent/PH12018500437A1/en unknown
- 2018-03-16 US US15/922,980 patent/US10329300B2/en active Active
- 2018-12-21 HK HK18116402.8A patent/HK1257146A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257146A1 (zh) | 新型的吡唑並[3,4-d]嘧啶化合物或其鹽 | |
HK1259623A1 (zh) | 作爲irak4調節劑的吡唑並[1,5a]嘧啶衍生物 | |
HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1,5-a]吡啶化合物 | |
ZA201905332B (en) | Novel condensed pyrimidine compound or salt thereof | |
HK1245764A1 (zh) | 3-取代的5-氨基-6h-噻唑並[4,5-d]嘧啶-2,7-二酮化合物 | |
HK1252752A1 (zh) | 新型吡唑並嘧啶衍生物 | |
IL257306B (en) | A compressed pyrimidine compound or a salt thereof | |
HK1256614A1 (zh) | 經取代的1,2-二氫-3h-吡咯並[1,2-c]咪唑-3-酮抗菌化合物 | |
ZA201605666B (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
IL262673A (en) | Pyrazolo[1,5-a]pyrimidine compound | |
EP3381916A4 (en) | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | |
HK1251232A1 (zh) | 吡咯並[2,3-d]嘧啶化合物或其鹽 | |
HUE050298T2 (hu) | Pirazolo[3,4-D]pirimidin vegyületek vagy annak sói |